Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

Abstract

We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.

Keywords

• Complicated urinary tract infections
• Gram-negative infection
• Hospital-acquired/ventilator-associated bacterial pneumonia
• Imipenem/cilastatin/relebactam